Diabetes Magna Plus™

Educational Resource · OCC Tijuana

Request Evaluation
Metabolic health education resource
Educational Resource · Not Medical Advice

Understanding Type 2 Diabetes & Metabolic Health

Learn about metabolic health, type 2 diabetes, obesity-related disease, and treatment pathways that may be considered as part of a physician-guided care plan.

Educational information designed to support informed healthcare decisions.

Request an Educational ConsultationStart Learning
JCI-Accredited Care Setting
Evidence-Informed Content
Clinician-Reviewed
Patient-Centered Education

Medical disclaimer: The information on this page is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Outcomes vary and are not guaranteed. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition.

Education

Understanding Type 2 Diabetes

Type 2 diabetes is a complex, multifactorial metabolic condition. Understanding the underlying mechanisms can help patients have informed conversations with their care team.

Insulin resistance

When cells respond less effectively to insulin, the pancreas compensates by producing more — often leading to elevated glucose over time.

Glucose metabolism

Type 2 diabetes involves dysregulation across multiple organs: liver, muscle, fat, gut, kidney, brain, and the pancreas itself.

Obesity-related metabolic disease

Excess visceral fat is associated with low-grade inflammation and contributes to insulin resistance and metabolic dysfunction.

A progressive condition

Type 2 diabetes can progress over time as beta-cell function declines. Treatment plans typically evolve and require ongoing follow-up.

Based on ADA Standards of Medical Care in Diabetes (most recent edition) and peer-reviewed endocrinology literature.

Education

Insulin Resistance Explained

Insulin resistance is a central feature of type 2 diabetes. Understanding it helps explain why blood glucose rises over time and why different treatment pathways exist.

Physiology

Insulin signals muscle, liver, and fat cells to take up glucose. In insulin resistance, that signal is blunted, so the pancreas secretes more insulin to compensate. Over years, beta-cell function can decline.

Risk factors

Family history, excess visceral adiposity, polycystic ovary syndrome (PCOS), sedentary lifestyle, certain medications, and disrupted sleep are commonly cited risk factors. (Sources: NIDDK; ADA.)

Relationship to type 2 diabetes

Insulin resistance plus relative beta-cell insufficiency leads to hyperglycemia. Prediabetes (A1c 5.7–6.4%) often reflects this state before diabetes thresholds are reached.

Lifestyle factors

Sustained weight reduction, regular aerobic and resistance training, improved sleep, and certain dietary patterns are associated with improved insulin sensitivity in many people.

Educational summary. Individualized evaluation is required to determine clinical significance.

Lab Test

Understanding HbA1c (A1c)

HbA1c is one of the most widely used measures in diabetes care. Knowing what it measures — and what it does not — supports informed conversations with your care team.

What A1c measures

The percentage of hemoglobin in red blood cells that is glycated, reflecting average blood glucose over the prior ~2–3 months. It does not capture day-to-day variability.

Common thresholds

Per ADA criteria: normal < 5.7%, prediabetes 5.7–6.4%, diabetes ≥ 6.5%. Diagnostic and treatment thresholds may differ for specific populations.

Common targets

ADA Standards of Care often cite an A1c goal of < 7% for many non-pregnant adults. Targets are individualized based on age, comorbidities, hypoglycemia risk, and patient preference.

Monitoring frequency

A1c is commonly measured every 3–6 months, depending on stability and treatment changes. Continuous glucose monitoring (CGM) data can complement A1c.

Long-term implications

Higher A1c over time is associated with increased risk of microvascular (kidney, eye, nerve) and macrovascular (heart, stroke) complications. Reducing A1c toward individualized targets is associated with lower complication risk in many trials.

Important caveats

Conditions affecting red blood cells (anemia, hemoglobinopathies, recent transfusion, pregnancy) can affect A1c accuracy. Clinicians may use alternate measures (fructosamine, CGM-derived GMI) when appropriate.

Sources: American Diabetes Association Standards of Medical Care in Diabetes (most recent edition); NIDDK patient education.

Education

The Relationship Between Weight & Metabolic Health

Body weight and body composition interact with multiple metabolic pathways. The relationship is bidirectional and influenced by many individual factors.

Obesity

A chronic, relapsing disease characterized by excess adiposity that can adversely affect health (WHO, AMA classifications).

Visceral fat

Fat surrounding internal organs that is metabolically active and associated with insulin resistance, dyslipidemia, and cardiovascular risk.

Insulin resistance

Reduced cellular response to insulin, a key driver of type 2 diabetes that is influenced by adiposity, activity, sleep, and genetics.

Cardiovascular risk factors

Hypertension, dyslipidemia, and chronic inflammation often cluster with obesity and contribute to long-term cardiovascular morbidity and mortality.

Treatment Pathways

Pathways That May Be Considered

A range of treatment pathways may be appropriate depending on individual health status, preferences, and physician evaluation. This overview is neutral and educational; no single pathway is right for everyone.

Nutrition

Evidence-based dietary patterns (Mediterranean, low-carbohydrate, structured meal planning) can support glycemic control and weight management.

Physical activity

Regular aerobic and resistance training are associated with improved insulin sensitivity and cardiovascular health.

Lifestyle interventions

Sleep, stress management, behavioral support, and smoking cessation each influence metabolic outcomes.

GLP-1 and other medications

Pharmacotherapy — including metformin, SGLT2 inhibitors, GLP-1 receptor agonists, insulin, and others — is selected by physicians based on individual factors.

Bariatric / metabolic surgery

Procedures such as sleeve gastrectomy, gastric bypass, and duodenal switch have published evidence in selected patients with obesity and type 2 diabetes.

Endoscopic interventions

Less-invasive endoscopic procedures (e.g., endoscopic sleeve gastroplasty) are an evolving option for selected patients.

The appropriateness of any pathway is determined through individualized physician evaluation. This page does not endorse one pathway over another.

Program Overview

What Is Diabetes Magna Plus™?

Diabetes Magna Plus™ is the name of a physician-guided educational and clinical program offered at Obesity Control Center (OCC) in Tijuana. The program focuses on metabolic health and individualized care planning.

  • Program philosophy

    Evidence-informed, patient-centered, multidisciplinary.

  • Clinical objectives

    Support metabolic health and informed decision-making with appropriate clinical oversight.

  • Physician evaluation process

    Comprehensive review of medical history, labs, and goals before any recommendation is made.

  • Individualized treatment planning

    Recommendations are tailored to the individual and may include lifestyle, medication, or procedural options when clinically appropriate.

Program participation does not imply candidacy for any specific procedure. All clinical decisions are made by qualified physicians on a case-by-case basis.

Illustration of magnetic anastomosis concept for educational reference

Illustrative reference. Refer to GT Metabolic Technologies and FDA documentation for device specifications and indications.

Patient Perspective

Why Patients Seek Comprehensive Diabetes Evaluation

Patients with type 2 diabetes often benefit from coordinated, individualized assessment that considers metabolic, nutritional, cardiovascular, and behavioral factors together.

Multidisciplinary care

Care that integrates physician evaluation, nutrition support, and behavioral health is described in clinical guidelines as supporting better outcomes for many people living with type 2 diabetes.

Long-term monitoring

Periodic A1c, lipid, kidney function, retinal, and foot exams help detect complications early. Long-term monitoring is recommended throughout the course of disease, including after remission.

Personalized treatment planning

Treatment selection considers diabetes duration, beta-cell reserve, comorbidities, prior interventions, and patient preferences. No single pathway is appropriate for everyone.

Evidence

What Does Current Evidence Suggest?

Below is a high-level summary of published evidence relevant to obesity and type 2 diabetes care. Findings vary across studies, populations, and procedures; individual outcomes differ.

Metabolic surgery evidence

Randomized trials (e.g., STAMPEDE, Diabetes Surgery Study) and large cohort studies suggest that, in selected patients with type 2 diabetes and obesity, metabolic surgery can improve glycemic control compared with medical therapy alone.

Diabetes remission studies

Published series report variable rates of diabetes remission after metabolic surgery, depending on procedure type, diabetes duration, and patient factors. Remission rates and durability differ across studies.

Long-term follow-up data

Long-term studies (e.g., SOS, STAMPEDE 5-year) describe sustained benefits in many patients alongside a meaningful rate of glycemic recurrence over time. Long-term monitoring is recommended.

Limitations of current evidence

Available studies vary in design, populations, follow-up duration, and definitions of remission. Newer devices and techniques may have less long-term data. Patients should review evidence with their physicians.

Important: Not every patient experiences the same outcome. Evidence describes group-level findings; it does not predict an individual's result.

Potential Benefits

Potential Benefits May Include

Published literature describes a range of potential benefits in selected patients. Benefits vary and are not guaranteed.

Potential benefits may include improved glucose control in selected patients.

Potential benefits may include reduced medication requirements for some patients.

Potential benefits may include support for weight management goals.

Potential benefits may include improvements in cardiovascular risk markers.

Education

Potential Complications of Type 2 Diabetes

Sustained hyperglycemia is associated with several long-term complications. Risk can often be reduced through individualized treatment, screening, and lifestyle factors.

Diabetic kidney disease

Diabetes is a leading cause of chronic kidney disease. Regular monitoring (eGFR, urine albumin) is recommended. (Source: NIDDK; ADA.)

Diabetic eye disease

Diabetic retinopathy can cause vision loss. Annual dilated eye exams are commonly recommended for adults with type 2 diabetes.

Diabetic neuropathy

Nerve damage can affect sensation, especially in the feet, and contribute to ulcers. Regular foot exams and glucose control are important preventive strategies.

Cardiovascular disease

People with diabetes have higher risk of coronary artery disease, stroke, and heart failure. Management of blood pressure, lipids, glucose, and lifestyle factors is central to risk reduction.

Educational summary. Individual risk and screening intervals are determined by your healthcare provider.

Safety

Risks & Considerations

All medical and surgical interventions carry risk. Patients should review risks and alternatives in detail with their physician as part of informed consent.

Surgical risks

May include bleeding, infection, anastomotic complications, anesthesia-related risks, and rare longer-term complications.

Medication risks

Pharmacotherapy carries side effects and contraindications that vary by drug class and individual factors.

Nutritional deficiencies

Some procedures may increase the risk of vitamin or mineral deficiencies, requiring lifelong supplementation and monitoring.

Disease progression

Type 2 diabetes can progress over time. Benefits from any intervention may diminish, and recurrence is possible.

Long-term monitoring

Ongoing laboratory monitoring, nutritional assessment, and medical follow-up are recommended after any metabolic intervention.

Individual variability

Outcomes depend on many factors and cannot be predicted for any given patient.

Important Distinction

Understanding Diabetes Remission

The medical concept of remission differs from the everyday meaning of cure. This distinction is important for setting accurate expectations.

Remission (consensus definition)

Per the 2021 international consensus (Riddle et al., Diabetes Care), HbA1c < 6.5% sustained for at least 3 months without glucose-lowering pharmacotherapy.

Partial remission

Historically described as sub-diabetic hyperglycemia (HbA1c 5.7–6.4%) sustained without medication. Definitions vary across guidelines.

Complete remission

Historically described as normal glycemic measures (HbA1c < 5.7%) sustained without medication. Definitions vary across guidelines.

Relapse

Recurrence of hyperglycemia meeting diabetes criteria after a period of remission. Risk factors include weight regain, reduced activity, and progression of beta-cell decline.

Long-term monitoring is recommended — even after remission.

Major society guidance supports continued periodic A1c testing and complications screening for people with a history of type 2 diabetes, including those in remission. Remission is a clinical category, not a guarantee.

Remission is not the same as cure.

Even when remission is achieved, type 2 diabetes can recur — particularly with weight regain or progression of underlying beta-cell decline. Continued monitoring and follow-up are recommended. No intervention guarantees permanent remission.

Candidacy

Who May Not Be an Ideal Candidate?

Not every patient is an appropriate candidate for every treatment. This section outlines situations that may warrant a different pathway or additional evaluation. Candidacy can only be determined through a qualified medical assessment.

Medical Considerations

  • •Active, unstable cardiopulmonary disease
  • •Untreated severe psychiatric illness or active substance use disorder
  • •Active malignancy or recent major surgery without clearance
  • •Pregnancy or planned pregnancy within 12–18 months of a procedure
  • •Type 1 diabetes (different physiology; requires different pathways)
  • •Severe coagulopathy or uncontrolled bleeding disorders

Lifestyle & Readiness Factors

  • •Inability or unwillingness to commit to long-term follow-up
  • •Lack of access to nutritional, medical, or behavioral support
  • •Unrealistic expectations about results or recovery
  • •Inability to adhere to post-procedure dietary or activity guidance

Alternative Treatment Options

  • •Structured lifestyle and medical nutrition therapy
  • •GLP-1 or GIP/GLP-1 receptor agonist therapy under physician supervision
  • •Insulin or other glucose-lowering medications
  • •Endoscopic procedures in selected patients
  • •Behavioral health, sleep, and stress-management programs

Situations Requiring Further Evaluation

  • •Recent cardiac events, unstable angina, or uncontrolled hypertension
  • •Advanced chronic kidney disease or significant liver dysfunction
  • •Complex prior abdominal surgery or anatomic considerations
  • •Significant nutritional deficiencies that should be corrected first

Educational content only. A qualified clinician must perform an individualized evaluation before any treatment recommendation.

Initial Consultation

What to Expect During Your Initial Consultation

A consultation is an information-gathering process, not a commitment to a procedure. The goal is to understand your medical situation and help you make an informed decision about next steps.

  1. 1

    Medical History Review

    Comprehensive review of diabetes history, medications, prior surgeries, comorbid conditions, family history, and prior weight or metabolic interventions.

  2. 2

    Physical Evaluation

    Vital signs, anthropometrics (BMI, waist circumference, body composition where available), and a focused physical exam relevant to metabolic and surgical risk.

  3. 3

    Diagnostic Testing

    Laboratory testing may include HbA1c, fasting glucose and insulin, lipid panel, kidney and liver function, thyroid studies, micronutrient screening, and additional cardiac or pulmonary evaluation when indicated.

  4. 4

    Goal Setting

    A collaborative discussion to define realistic, individualized goals — glycemic targets, weight, functional capacity, medication burden, and quality-of-life priorities.

  5. 5

    Risk Discussion

    Transparent review of the risks, benefits, and limitations of each option being considered, including the possibility that no procedure is recommended.

  6. 6

    Treatment Discussion

    Review of physician-guided pathways that may apply — lifestyle and medical therapy, pharmacotherapy (including GLP-1 agents), endoscopic options, or metabolic surgery.

  7. 7

    Alternative Options

    Explicit discussion of reasonable alternatives, including continuing current medical management or seeking a second opinion.

Treatment Alternatives

Reasonable Alternatives to Consider

Multiple treatment pathways exist for type 2 diabetes and obesity-related metabolic disease. The right approach depends on individual medical history, goals, and preferences. No single option is universally superior.

Lifestyle & Medical Nutrition Therapy

Benefits
Non-invasive, supports overall health, foundational for any treatment plan, and may achieve meaningful improvements in selected patients.
Limitations
Requires sustained behavior change; magnitude of A1c reduction varies; remission with lifestyle alone is uncommon in long-standing diabetes.
Differences
First-line approach recommended by major societies; complements rather than replaces other treatments when needed.

GLP-1 / GIP-GLP-1 Pharmacotherapy

Benefits
Improves glycemic control, supports weight reduction, and certain agents have demonstrated cardiovascular benefit in trials.
Limitations
Generally long-term therapy; gastrointestinal side effects are common; benefits may diminish after discontinuation; cost and access vary.
Differences
Pharmacologic, ongoing therapy rather than a one-time intervention; requires monitoring.

Insulin & Other Glucose-Lowering Medications

Benefits
Effective glucose control across a wide range of patients, including advanced disease.
Limitations
Risk of hypoglycemia (especially with insulin and sulfonylureas), weight gain with certain agents, and ongoing self-management demands.
Differences
Standard medical management; can be combined with lifestyle, GLP-1s, or procedural pathways.

Endoscopic Procedures

Benefits
Less invasive than surgery; shorter recovery for selected patients.
Limitations
Outcomes generally more modest than surgical options; long-term durability still being studied; not appropriate for all anatomies.
Differences
Minimally invasive option that may serve as a bridge or alternative in selected patients.

Metabolic & Bariatric Surgery

Benefits
Substantial and durable weight reduction and glycemic improvement in selected patients; remission documented in a subset.
Limitations
Surgical and anesthesia risks, possible nutritional deficiencies, lifelong follow-up, and recurrence is possible.
Differences
Anatomic intervention with the largest average effect size in published trials, but with corresponding risk profile.

Recovery

Recovery Timeline & Long-Term Follow-Up

Recovery experiences vary by patient, procedure, and overall health. The timeline below is a general educational guide — your clinical team will provide an individualized plan.

Day 1

Inpatient observation, pain and nausea management, early mobilization, and gradual introduction of clear liquids per protocol.

Week 1

Liquid diet phase, gradual return to light daily activity, wound care, and close clinical contact. Fatigue is common.

Week 2

Transition to pureed or soft foods as tolerated, structured hydration, and continued activity reintroduction.

Month 1

Progression to a solid, protein-prioritized diet under nutritional guidance; many patients return to most non-strenuous activity.

Month 3

Repeat metabolic labs (often including A1c), nutrition review, and medication adjustment with the treating clinician.

Month 6

Comprehensive follow-up: glycemic trends, micronutrient screening, weight trajectory, and review of long-term plan.

Year 1 & Beyond

Annual labs, micronutrient monitoring, lifestyle reinforcement, and surveillance for relapse, complications, or weight regain.

Individual recovery varies. Follow the post-procedure instructions provided by your clinical team and report concerning symptoms promptly.

Patient Journey

The Patient Journey — Step by Step

Patient care is a continuum, not a single event. Understanding the full journey helps set realistic expectations and supports long-term success.

  1. Step 1
    Inquiry

    Initial educational research and information request.

  2. Step 2
    Consultation

    Discussion with a clinician about goals, options, and risks.

  3. Step 3
    Evaluation

    Medical history, physical exam, labs, and risk assessment.

  4. Step 4
    Treatment Planning

    Individualized plan developed collaboratively with the patient.

  5. Step 5
    Procedure or Treatment

    The chosen medical, pharmacologic, or procedural pathway.

  6. Step 6
    Recovery

    Structured recovery with nutritional and clinical support.

  7. Step 7
    Long-Term Follow-Up

    Ongoing monitoring, lifestyle support, and surveillance.

Physician Perspective

Insights from the Clinical Team

Educational reflections from clinicians who care for patients with type 2 diabetes and obesity-related metabolic disease.

Clinical Insight

“One of the most common misconceptions patients have is…”

…that a procedure alone will manage diabetes long-term. Sustainable results depend on the combination of intervention, nutrition, activity, sleep, mental health, and consistent follow-up. The procedure is a tool — not a cure.

Clinical Insight

“Patients frequently ask whether remission means they are cured.”

Remission and cure are not the same. Remission means glycemic measures are within a defined range without medication for a defined period. The underlying metabolic vulnerability remains, so monitoring and lifestyle continue to matter.

Clinical Insight

“What surprises patients most about recovery?”

How much energy and patience the early weeks require. Most patients feel better progressively, but progress is rarely linear. Following the staged nutrition plan and staying in contact with the care team are the most reliable predictors of a smooth recovery.

Clinical Insight

“When is the right time to consider intervention?”

There is no single right time. The decision is shaped by diabetes duration, A1c trend, complications, response to medical therapy, and individual goals. Earlier evaluation gives more options; it does not commit a patient to any specific path.

Program Overview

Why Patients Consider This Program

Objective criteria patients commonly weigh when evaluating a metabolic care program. These are educational descriptors, not claims of superiority.

Experience

Surgeons and clinicians with focused training and high case volume in bariatric and metabolic care.

Accreditation

Care delivered in a Joint Commission International (JCI) accredited facility, with documented quality and safety standards.

Patient Education

Structured educational materials and consultations to support informed decision-making before any treatment.

Long-Term Follow-Up

Scheduled post-procedure follow-up with labs and clinical review to support durable outcomes.

Multidisciplinary Care

Coordinated team including surgery, internal medicine, nutrition, and behavioral health where indicated.

Technology

Use of contemporary clinical tools and platforms supported by published evidence.

Patient Support

Patient coordinators and care navigators who support communication before, during, and after care.

Why Patients Trust

Why Patients Trust Obesity Control Center

Independent accreditations, regulatory references, and program-level outcomes that patients can verify.

25+

Years of clinical experience

Source

30,000+

Bariatric & metabolic procedures performed

Source

JCI

Joint Commission International accredited

Source

SRC

Surgical Review Corporation — Center of Excellence

Source

GHA

Global Healthcare Accreditation — medical travel

Source

19,801

Patients in published OCC outcomes review

Source

See all sources & verification →

Accreditation, certification, and society membership do not guarantee individual outcomes. Statistics reflect program-level findings.

Editorial Standards

Medical Review & Clinical Oversight

The educational content on this website is reviewed for medical accuracy, clarity, and patient safety by experienced bariatric and metabolic surgery professionals. The purpose of this review is to help ensure that information about obesity treatment, bariatric surgery, metabolic health, revisional surgery, endoscopic procedures, GLP-1 medications, and long-term follow-up is presented responsibly and without exaggerated claims.

Medical Reviewers

Dr. Ariel Ortiz Lagardere, MD, FACS, FASMBS

Bariatric & Metabolic Surgeon

Founder and Director, Obesity Control Center

Dr. Ariel Ortiz Lagardere is a bariatric and metabolic surgeon with extensive experience in minimally invasive weight-loss surgery, metabolic disease treatment, international patient care, and surgical education. Public professional profiles describe him as board-certified in Mexico, a Fellow of the American College of Surgeons, a Fellow of the American Society for Metabolic and Bariatric Surgery, and an SRC-recognized Master Surgeon in Metabolic and Bariatric Surgery.

Dr. Arturo Martinez Gamboa, MD

Bariatric & Metabolic Surgeon

Obesity Control Center

Dr. Arturo Martinez Gamboa has been affiliated with Obesity Control Center since 2001. His publicly available professional biography describes advanced laparoscopic and bariatric training at Hospital Ramón y Cajal in Madrid, Spain. Surgical Review Corporation sources identify him as an SRC-accredited Master Surgeon in Metabolic & Bariatric Surgery and Bariatric Revisional Surgery.

Dr. Helmuth Billy, MD

Bariatric & Revisional Surgery Specialist

Ventura, California

Dr. Helmuth Billy is a bariatric surgeon specializing in laparoscopic bariatric surgery, revisional bariatric surgery, and multidisciplinary weight-loss care. Public ASMBS meeting biographies describe him as being in private practice since 1997, actively practicing bariatric surgery since 2000, serving as medical director at two MBSAQIP hospitals, and having a clinical interest in weight regain and revisional surgery.

Editorial Review Process

All medical content is periodically reviewed for accuracy, relevance, readability, and consistency with current medical knowledge and accepted bariatric and metabolic surgery principles. Content is intended to support informed decision-making and does not replace consultation with a qualified healthcare professional.

Educational Disclaimer

This website provides general educational information only. It does not provide medical advice, diagnosis, treatment recommendations, or guarantees of outcome. Candidacy for any medical, surgical, endoscopic, or medication-based treatment must be determined by a qualified healthcare professional after an individual evaluation.

Review Schedule

Last reviewed: June 1, 2026
Next scheduled review: December 1, 2026
Sources: ASMBS, IFSO, NIH/NIDDK, ADA, AACE, and peer-reviewed bariatric and metabolic literature.

Related Resources

Related Educational Resources

Additional educational resources covering related metabolic and bariatric topics.

MagnaMetabolic.com

Broader educational resource on magnetic anastomosis platforms across metabolic disease.

GLPSurgery.com

Education at the intersection of GLP-1 therapy and surgical options.

SleevePlus.mx

Patient education on sleeve gastrectomy approaches.

EndoscopicSleeve.mx

Information on endoscopic sleeve gastroplasty.

SleeveTijuana.com

Patient information on sleeve gastrectomy in Tijuana.

MiniBypassMexico.com

Educational overview of mini gastric bypass.

FAQ

Frequently Asked Questions

Educational answers, not medical advice.

Type 2 diabetes is a chronic condition in which the body's cells respond less effectively to insulin (insulin resistance) and the pancreas progressively loses the ability to produce enough insulin to keep blood glucose in range. It is influenced by genetics, body weight, physical activity, sleep, and other factors. (Source: ADA Standards of Care; NIDDK.)

References

References & Further Reading

Statements on this page are informed by the following peer-reviewed and official sources. Readers are encouraged to consult primary sources and their physicians.

  1. American Diabetes Association. Standards of Medical Care in Diabetes (most recent edition).

    Diabetes Care, annual supplement. diabetes.org

  2. American Association of Clinical Endocrinology (AACE). Comprehensive Type 2 Diabetes Management Algorithm.

    Endocrine Practice. aace.com

  3. Riddle MC, et al. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes.

    Diabetes Care, 2021;44(10):2438–2444.

  4. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Type 2 Diabetes patient education.

    niddk.nih.gov

  5. National Institutes of Health (NIH). Diabetes research and clinical information.

    nih.gov

  6. World Health Organization. Diabetes fact sheets and global reports.

    who.int/health-topics/diabetes

  7. Centers for Disease Control and Prevention. National Diabetes Statistics Report.

    cdc.gov/diabetes/data

  8. International Diabetes Federation. IDF Diabetes Atlas (most recent edition).

    idf.org/diabetesatlas

  9. Schauer PR, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes (STAMPEDE).

    N Engl J Med, 2017;376:641–651.

  10. Sjöström L, et al. Association of bariatric surgery with long-term remission of type 2 diabetes (SOS Study).

    JAMA, 2014;311(22):2297–2304.

  11. Rubino F, et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes — 2nd Diabetes Surgery Summit.

    Diabetes Care, 2016;39(6):861–877.

  12. Mingrone G, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes — 10-year follow-up.

    Lancet, 2021;397(10271):293–304.

  13. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).

    N Engl J Med, 2016;375:1834–1844.

  14. GT Metabolic Technologies. MagDI™ device technical and regulatory documentation.

    Refer to manufacturer materials and FDA clearance documents.

Content Review Statement

Content on this page is developed and reviewed by healthcare professionals experienced in metabolic disease and bariatric surgery at Obesity Control Center, a Joint Commission International (JCI) accredited facility. Content is reviewed periodically and updated as the evidence base evolves. This page is educational and is not a substitute for individualized medical advice.

Last reviewed: June 1, 2026

Reviewed by: Obesity Control Center clinical team

Request an Educational Consultation

Submit your information to receive educational materials and information about physician-led evaluation. A patient coordinator may follow up. Submitting this form is not a guarantee of candidacy, treatment, or any specific outcome.

No obligation; educational purpose
Reviewed by OCC's clinical team
Your information is handled per our Privacy Policy

Educational Information Request

Submission is not a guarantee of candidacy, treatment, or any specific outcome.